Evidence map›Paper›PMID 38742836›Full record

ArticleHealth expectations : an international journal of public participation in health care and health policy2024

The experiences and perspectives of people with gout on urate self-monitoring.

Toni J F Michael, Jian S Chan, Stephen Hughes, Daniel F B Wright, Matthew J Coleshill, Dyfrig A Hughes, Richard O Day, Parisa Aslani, Sophie L Stocker

Abstract read
In one paragraph

Article in Health expectations : an international journal of public participation in health care and health policy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. The experiences and perspectives of people with gout on urate self-monitoring.Health expectations : an international journal of public participation in health care and health policy · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Toni J F MichaelSchool of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.ORCID 0000-0002-6422-8683
Jian S ChanSt Vincent's Clinical School Campus, Faculty of Medicine, The University of New South Wales, Sydney, New South Wales, Australia.ORCID 0000-0002-4479-7926
Stephen HughesSchool of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.ORCID 0000-0002-3633-5203
Daniel F B WrightSchool of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.ORCID 0000-0001-9313-9252
Matthew J ColeshillBlack Dog Institute, Faculty of Medicine, The University of New South Wales, Sydney, New South Wales, Australia.ORCID 0000-0003-1906-1893
Dyfrig A HughesCentre for Health Economics and Medicines Evaluation, North Wales Medical School, Bangor University, Wales, UK.ORCID 0000-0001-8247-7459
Richard O DaySt Vincent's Clinical School Campus, Faculty of Medicine, The University of New South Wales, Sydney, New South Wales, Australia.ORCID 0000-0002-6045-6937
Parisa AslaniSchool of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.ORCID 0000-0002-7976-8236
Sophie L StockerSchool of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Sydney, New South Wales, Australia.ORCID 0000-0002-2114-587X

Funding

Arthritis Australia project grant.
6 · The paper itself

Abstract

introductionGout management remains suboptimal despite safe and effective urate-lowering therapy. Self-monitoring of urate may improve gout management, however, the acceptability of urate self-monitoring by people with gout is unknown. The aim of this study was to explore the experiences of urate self-monitoring in people with gout.

methodsSemistructured interviews were conducted with people taking urate-lowering therapy (N = 30) in a 12-month trial of urate self-monitoring in rural and urban Australia. Interviews covered the experience of monitoring and its effect on gout self-management. Deidentified transcripts were analysed thematically.

resultsParticipants valued the ability to self-monitor and gain more understanding of urate control compared with the annual monitoring ordered by their doctors. Participants indicated that self-monitoring at home was easy, convenient and informed gout self-management behaviours such as dietary modifications, hydration, exercise and medication routines. Many participants self-monitored to understand urate concentration changes in response to feeling a gout flare was imminent or whether their behaviours, for example, alcohol intake, increased the risk of a gout flare. Urate concentrations were shared with doctors mainly when they were above target to seek management support, and this led to allopurinol dose increases in some cases.

conclusionUrate self-monitoring was viewed by people with gout as convenient and useful for independent management of gout. They believed self-monitoring achieved better gout control with a less restricted lifestyle. Urate data was shared with doctors at the patient's discretion and helped inform clinical decisions, such as allopurinol dose changes. Further research on implementing urate self-monitoring in routine care would enable an evaluation of its impact on medication adherence and clinical outcomes, as well as inform gout management guidelines. PATIENT OR PUBLIC CONTRIBUTION: One person with gout, who was not a participant, was involved in the study design by providing feedback and pilot testing the semistructured interview guide. In response to their feedback, subsequent modifications to the interview guide were made to improve the understandability of the questions from a patient perspective. No additional questions were suggested.

Indexed as

GoutInterviews as TopicUric AcidAdultAgedAustraliaFemaleGout SuppressantsHumansMaleMiddle AgedQualitative ResearchSelf CareSelf-ManagementGout SuppressantsUric Acidadherencegoutpatient‐ledpoint‐of‐carequalitativeself‐monitoringurate

Identifiers

PMID38742836
PMCPMC11092534

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.